Celadon Pharmaceuticals PLC (LSE:CEL) — Stock Price
Celadon Pharmaceuticals PLC (LSE:CEL) is currently trading at GBX13.40 GBX, up 0.00% today. Over the past 52 weeks, shares have ranged between GBX13.40 and GBX13.40. This page tracks Celadon Pharmaceuticals PLC's live share price on the LSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Celadon Pharmaceuticals PLC (CEL) market capitalisation.
Celadon Pharmaceuticals PLC (CEL) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Celadon Pharmaceuticals PLC's daily closing share price and trading volume on the LSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Daily price history is not currently available for Celadon Pharmaceuticals PLC.
Celadon Pharmaceuticals PLC Income Statement — Revenue, Profit & Earnings by Year
Celadon Pharmaceuticals PLC's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Total Revenue | GBX75.00K | GBX24.00K | GBX2.00K | GBX0.00 |
| Cost of Revenue | GBX74.00K | GBX90.00K | GBX12.00K | GBX0.00 |
| Gross Profit | GBX1.00K | GBX-66.00K | GBX-10.00K | GBX0.00 |
| Research & Development | — | — | — | GBX217.11K |
| SG&A | — | — | — | GBX255.84K |
| Total Operating Expenses | GBX5.76 Million | GBX12.85 Million | GBX2.70 Million | GBX720.65K |
| Operating Income | GBX-5.93 Million | GBX-5.38 Million | GBX-2.71 Million | GBX-720.65K |
| EBITDA | GBX-6.39 Million | GBX-13.61 Million | GBX-2.39 Million | GBX-660.25K |
| EBIT | GBX-6.92 Million | GBX-14.08 Million | GBX-2.71 Million | GBX-720.65K |
| Interest Expense | GBX598.00K | GBX4.04 Million | GBX646.00K | GBX339.15K |
| Income Before Tax | GBX-7.52 Million | GBX-18.12 Million | GBX-4.80 Million | GBX-1.06 Million |
| Income Tax Expense | GBX-261.00K | GBX-707.00K | GBX-13.00K | GBX339.15K |
| Net Income | GBX-7.14 Million | GBX-17.41 Million | GBX-4.78 Million | GBX-1.40 Million |
Celadon Pharmaceuticals PLC Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Celadon Pharmaceuticals PLC's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Total Assets | GBX9.22 Million | GBX13.25 Million | GBX6.61 Million | GBX3.85 Million | GBX2.49 Million |
| Total Current Assets | GBX2.50 Million | GBX6.33 Million | GBX6.61 Million | GBX737.21K | GBX2.60K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | GBX75.00K | GBX1.06 Million | GBX2.13 Million | GBX599.00 | GBX300.00 |
| Inventory | GBX100.00K | GBX20.00K | GBX2.00K | GBX427.95K | GBX-14.56K |
| Property, Plant & Equipment | — | GBX6.28 Million | — | GBX3.03 Million | — |
| Goodwill | GBX80.00K | GBX80.00K | GBX719.00K | GBX80.30K | GBX0.00 |
| Total Liabilities | GBX6.04 Million | GBX6.21 Million | GBX197.23K | GBX3.75 Million | GBX2.60 Million |
| Total Current Liabilities | GBX955.00K | GBX1.20 Million | GBX176.93K | GBX834.86K | GBX66.82K |
| Long-term Debt | GBX14.00K | GBX24.00K | — | GBX43.33K | GBX0.00 |
| Net Debt | GBX3.46 Million | GBX-429.00K | GBX7.12 Million | GBX2.62 Million | GBX2.53 Million |
| Total Stockholder Equity | GBX3.16 Million | GBX7.67 Million | GBX6.41 Million | GBX99.03K | GBX-113.47K |
| Retained Earnings | GBX-30.73 Million | GBX-22.81 Million | GBX-1.09 Million | GBX-1.17 Million | GBX-113.77K |
Celadon Pharmaceuticals PLC Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Celadon Pharmaceuticals PLC generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | GBX-5.97 Million | GBX-6.10 Million | GBX-3.15 Million | GBX-77.57K | GBX1.98K |
| Capital Expenditures | GBX341.00K | GBX2.09 Million | GBX542.00K | GBX708.24K | GBX0.00 |
| Free Cash Flow | GBX-6.31 Million | GBX-8.19 Million | GBX-3.69 Million | GBX-785.82K | GBX1.98K |
| Investing Cash Flow | GBX-341.00K | GBX1.39 Million | GBX-1.24 Million | GBX-697.03K | — |
| Financing Cash Flow | GBX2.51 Million | GBX5.95 Million | GBX7.91 Million | GBX1.07 Million | GBX5.82 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | GBX285.00K | GBX7.31 Million | GBX0.00 | — | — |
| Depreciation | GBX534.00K | GBX466.00K | GBX319.00K | GBX160.85K | GBX33.48K |
| Change in Cash | GBX-3.80 Million | GBX1.24 Million | GBX3.52 Million | GBX297.99K | GBX5.82 Million |
Celadon Pharmaceuticals PLC Earnings History — EPS Actual vs. Analyst Estimates
Track Celadon Pharmaceuticals PLC's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 29, 2025 | — | — | — |
| May 29, 2025 | — | — | — |
| Sep 30, 2024 | -0.04 | 0.00 | — |
| Sep 29, 2022 | -0.03 | — | — |
| Nov 30, 2021 | -0.03 | 0.00 | — |
| May 11, 2021 | -0.03 | 0.00 | — |
| Feb 04, 2021 | -0.01 | 0.00 | — |
| May 19, 2020 | -0.03 | 0.00 | — |